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ABSTRACT
Objective: To investigate the association of non-
steroidal anti-inflammatory drugs (NSAIDs) and the
risk of atrial fibrillation in a prospective community-
based follow-up study of elderly individuals with
uniform case assessment and data on potential
confounders.
Design: Data came from the population-based follow-
up study, the Rotterdam Study.
Participants: The study comprised 8423 participants
without atrial fibrillation at baseline.
Main outcome measures: Atrial fibrillation was
ascertained from ECG assessments as well as medical
records. Use of NSAIDs was obtained from automated
prescription records by linkage with participating
pharmacies. We used Cox proportional hazards models
to study the association between NSAID drug use and
atrial fibrillation. Use of NSAIDs was included in the
model as a time-varying variable.
Results: At baseline, the mean age of the study
population was 68.5 years (SD: 8.7) and 58% were
women. During a mean follow-up of 12.9 years, 857
participants developed atrial fibrillation. Current use of
NSAIDs was associated with increased risk compared
with never-use (HR 1.76, 95% CI 1.07 to 2.88). Also,
recent use (within 30 days after discontinuation of
NSAIDs) was associated with an increased risk of atrial
fibrillation compared with never-use (HR 1.84, 95% CI
1.34 to 2.51) adjusted for age, sex and several
potential confounders.
Conclusions: In this study, use of NSAIDs was
associated with an increased risk of atrial fibrillation.
Further studies are needed to investigate the underlying
mechanisms behind this association.
INTRODUCTION
Atrial fibrillation (AF) is a common cardiac
arrhythmia in the elderly, which is associated
with increased morbidities (eg, stroke1 and
heart failure2), increased mortality and
reduced life expectancy.3–5 Several drugs
have been associated with an increased risk
of AF including steroidal anti-inflammatory
drugs.6 7 Recently, some studies suggested
that non-steroidal anti-inflammatory drugs
(NSAIDs) are also associated with a higher
risk of AF.8–10 NSAIDs are inhibitors of cyclo-
oxygenase, and are widely used to treat
inflammatory conditions and pain. Use of
NSAIDs has previously been associated with a
higher risk of myocardial infarction, stroke
and heart failure.11–14 Moreover, NSAID use
has been associated with increased cardiac
dimensions such as left ventricular end-
diastolic and systolic dimensions obtained
with echocardiography.15
The previous studies investigating the asso-
ciation between NSAIDs and AF are mainly
retrospective case–control studies or claims
database studies with limited availability of
potential confounders. Therefore, the object-
ive of this study was to investigate whether
Strengths and limitations of this study
▪ In this study, we included follow-up data from
the Rotterdam Study, which is based in the
general population and contains detailed infor-
mation on drug exposure. Compared with previ-
ous database studies, we were able to use more
detailed information for a range of potential con-
founders and to adjust for established risk
factors of atrial fibrillation such as blood pres-
sure and body mass index, and in a subsample
for echocardiographic measures. Also, we were
able to use a more detailed clinical assessment
of atrial fibrillation. We used three different
methods for case gathering and assessment, as
we included every clinically recognised case
from two different sources of medical records. In
addition, we included repeated screening ECG
assessments of the study population at the
research centre.
▪ Compared with the previously published studies,
however, our sample size was smaller. This
might explain why some of our estimations did
not reach statistical significance.
▪ Our study may have missed over-the-counter use
of NSAIDs.
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use of NSAIDs is associated with AF in a prospective
population-based cohort study with precise data on inci-
dent AF, complete information on drug use and poten-
tial confounders.
METHODS
Study population
The current study was performed within the Rotterdam
Study (RS), a population-based prospective cohort study,
designed to examine the onset of, and risk factors for,
disease in older adults. For this study, we combined parti-
cipants from RS cohort 1 (RS-I), which started with a
baseline visit between 1990 and 1993 (n=7983), and from
RS cohort 2 (RS-II), which started with a baseline visit
between 2000 and 2001 (n=3011).16 All participants aged
55 years and over who lived in the Ommoord district of
Rotterdam, The Netherlands, were invited to participate.
At baseline, participants were interviewed at home and
examined at the research centre, which included a 10 s,
12-lead resting ECG. From that visit onwards, participants
were followed continuously and re-examined. For the
current study, we used data from three follow-up examin-
ation rounds (1993–1995, 1997–1999 and 2002–2004) for
RS-I, and from one re-examination round (2004–2005)
for RS-II. Information on the presence and occurrence
of disease at baseline and during follow-up is available by
integrating information gathered by general practitioners
in the study area.17 General practitioners in the
Netherlands have a central and coordinating position in
the Dutch Health Care system. They register all diagnoses
available from their own work and from the work from
physicians in the hospital and the outpatient clinic.
Information on vital status was obtained on a regular
basis from the Central Register of Population of the
municipality of Rotterdam, from collaborating general
practitioners, and by collecting information during
follow-up examination rounds. For the participants for
whom information remained missing, the Central
Registry of Genealogy of the Netherlands was consulted.
This national institute receives population registry
records of all inhabitants of the Netherlands who have
died. All participants were followed from their baseline
ECG assessment without AF until the date of diagnosis of
incident AF, the date of death, loss to follow-up or end of
the study period on 1 January 2009, whichever came first.
AF assessment
Prevalent and incident AF was ascertained using three
methods.18 At baseline and at each follow-up examin-
ation, an ECG was recorded, stored digitally and analysed
by the modular ECG analysis system (MEANS).19–21
Notably, MEANS is characterised by high sensitivity
(96.6%) and high specificity (99.5%) in coding arrhyth-
mias.19 To verify the diagnosis of AF, all ECGs with a diag-
nosis of AF, atrial flutter or any other rhythm disorder
were coded independently by two research physicians
who were blinded to the MEANS diagnosis. The
judgement of a cardiologist was taken as decisive in those
cases in which disagreement persisted between the
coding physicians. In addition, information was obtained
from the treating general practitioners, which included
their own results as well as results from medical specialists
practising in hospitals and outpatient clinics. Patients
were considered as a case of AF after diagnosis by a
medical specialist or diagnosis by a general practitioner
with ascertainment from an ECG. Finally, information
was obtained from a Nationwide Medical Registry (LMR)
of all hospital discharge diagnoses. The date of incident
AF was defined as the date of the first occurrence of
symptoms with subsequent ECG verification. We did not
distinguish between AF and atrial flutter when we identi-
fied cases because both conditions are very similar with
respect to risk factors and consequences.22 23
Drug exposure
Complete information on all filled prescriptions for all
participants of the RS was obtained in an automated
format from the collaborating pharmacies. This
included the product name, international non-
proprietary name, Anatomical Therapeutic Chemical
code, total number of delivered units (eg, tablets or cap-
sules), prescribed daily number of units, date of delivery
and drug dosage. The duration of a prescription was cal-
culated as the total number of delivered units divided by
the prescribed daily number of units. The prescribed
daily drug dosage was expressed in defined daily dose
units, the recommended daily dosage of a drug taken by
adults for the main indication of the drug by the
WHO.24
Covariable assessment
Body mass index (BMI) was calculated by dividing body
weight in kilograms by squared height in metres. Blood
pressure was measured twice at the right upper arm with
a random zero mercury sphygmomanometer in the
sitting position. The systolic and diastolic blood pres-
sures were calculated as the average of the two consecu-
tive measurements. Serum total cholesterol and
high-density lipoprotein (HDL) cholesterol levels were
measured with an automated enzymatic method. The
presence of a myocardial infarction is based on clinical
information from the medical records. For participants
of the original RS-I cohort, the presence of myocardial
infarction at baseline is based on verification of either
self-reported myocardial infarction or ECG abnormal-
ities indicative of prior myocardial infarction. In all sub-
sequent cohorts and during follow-up, the medical
records of all participants are screened, regardless of
their self-reported history or ECG abnormalities. This
information was independently validated by two cardio-
vascular research physicians.17 In cases in which the
research physicians disagreed, judgement of a medical
specialist was considered decisive.17 Heart failure was
assessed using a validated score based on the definition
of heart failure by the European Society of
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Cardiology.25 26 Prevalent diabetes mellitus was defined
as a preload or postload serum glucose level of
>11 mmol/L determined at a research visit or the use of
hypoglycaemic medication.27
Statistical analysis
To study the association between NSAID drug use and
AF, we used Cox proportional hazards models. Use of
NSAIDs was included in the model as a time-varying cov-
ariable as described earlier.28 During follow-up, each
time an event of AF occurred (index date), we deter-
mined the exposure to NSAIDs in each case and in the
remainder of the cohort of participants on the same day
of follow-up. Persons were considered as current users of
an NSAID if an event date fell between the start date
and end date of a prescription. If a person had previ-
ously used an NSAID but no longer used the drug on an
event date, they were considered as a past user.
Participants were categorised as current users (distin-
guished into: use ≤14; 15–30; >30 days), past users (dis-
tinguished into: stopped ≤30; 31–180; >180 days ago)
and never users. Persons who had not used an NSAID at
any time during the study period were categorised as
‘never users’. Also, we studied whether the prescribed
dosage of current users was associated with the risk of
AF. All analyses were adjusted for age at index date and
sex. In a second model, we additionally adjusted for
established risk factors for AF including baseline values
of systolic blood pressure, diastolic blood pressure, BMI,
total and HDL cholesterol, smoking status and time-
dependent covariables: blood pressure lowering drug
use, history of myocardial infarction, presence of heart
failure and presence of diabetes. Missing data for these
covariates were imputed using an expectation maximisa-
tion algorithm. As NSAID use has been associated with
an increased left ventricular end-diastolic dimension
obtained by echocardiography,15 we hypothesised that
this could explain the association of NSAID use with AF.
Therefore, we additionally adjusted for left ventricular
end-diastolic dimension in a sensitivity analysis. In this
analysis, participants were followed from the date of the
echocardiographic examination (fourth research centre
visit RS-I: 2002–2004, second research centre visit RS-II:
2004–2005) onwards (n=4919).
RESULTS
The total population of cohorts RS-I and RS-II consisted
of 10 994 participants (7983 from the first cohort and
3011 from the second cohort). Of these, 459 partici-
pants had been diagnosed with AF at the baseline of the
study and 2112 had missing information on AF status or
drug exposure and were therefore excluded from the
analysis. This resulted in a population for analysis of
8423 participants. At baseline, the mean age of the study
population was 68.5 years (SD 8.7), of whom the major-
ity were women (58.6%; table 1). During a mean
follow-up of 12.9 years, 857 participants developed AF.
At the moment of diagnosis of AF, 261 cases had never
used NSAIDs, 554 had used NSAIDs in the past, and 42
were currently using NSAIDs. Of these current users, the
majority (n=29) used a non-selective NSAID, five partici-
pants used a COX-1 selective NSAID, and seven used a
COX-2 selective NSAID.
NSAIDs and the risk of AF
Current use of NSAIDs for 15–30 days was associated
with an increased risk of AF compared with never use
(HR 1.76, 95% CI 1.07 to 2.88 adjusted for age, sex and
cardiovascular risk factors; table 2). Also, recent past use
of NSAIDs, being use within the preceding 30 days, was
associated with an increased risk of AF (HR 1.84, 95%
CI 1.34 to 2.51 adjusted for age, sex and cardiovascular
risk factors). Although higher dosages seemed to be
associated with a higher risk of AF, this did not reach
statistical significance.
In a sensitivity analysis, we additionally adjusted for left
ventricular end-diastolic dimension (table 3). In this
analysis, left ventricular end-diastolic dimension was asso-
ciated with an increased risk of AF (HR per SD incre-
ment: 1.17, 95% CI 1.01 to 1.35 adjusted for age, sex,
NSAID use and cardiovascular risk factors). However,
even after adjusting for left ventricular dimension,
current NSAID use was associated with AF (HR 15–
30 days: 3.21, 95% CI 1.21 to 8.48, adjusted for age, sex
and left ventricular end-diastolic dimension and cardio-
vascular risk factors) compared with never use. Similar
results were found adjusting for left ventricular end sys-
tolic dimension or left atrial size (table 3).
DISCUSSION
Our results suggest that NSAID use is associated with a
higher risk of AF. Current use and recent past use were
associated with a higher risk of AF, adjusted for age, sex
and cardiovascular risk factors. Also, after additional
Table 1 Baseline characteristics of study population
(N=8423)
Mean (SD)/N (%)
Age (years) 68.5 (8.7)
Female sex 4940 (58.6)
Systolic blood pressure (mm Hg) 140 (22)
Diastolic blood pressure (mm Hg) 75 (11)
Blood pressure lowering drugs 2828 (33.6)
Body mass index (kg/m2) 26.5 (3.8)
Total cholesterol 6.4 (1.2)
HDL cholesterol 1.4 (0.4)
Current smoker 1845 (21.9)
Past smoker 3643 (43.3)
History of myocardial infarction 791 (9.4)
Presence of congestive heart failure 160 (1.9)
Presence of diabetes mellitus 864 (10.4)
HDL, high-density lipoprotein.
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adjustment for echocardiographic parameters, current
NSAID use was associated with an increased risk of AF.
Previously, a case–control study from the UK with data
from the General Practice Research Database showed
that current use of NSAIDs was associated with an
increased risk of AF.8 These results were later replicated
by Schmidt et al9 in a population-based case–control
study in Denmark. They showed that use of NSAIDs was
associated with an increased risk of AF. Furthermore,
their results suggested that the risk of AF was strongest
for COX-2 inhibitors, which was later confirmed by
others.10 Our results support most of these previously
published results but also suggest that the increased risk
occurs shortly after starting treatment and may dis-
appear over time. Schmidt et al also showed that longer
current use was not associated with an increased risk of
AF. There are two possible explanations for these results.
First, it is possible that these results can be explained by
‘depletion of susceptibles’ if those with symptoms dis-
continue drug use. Also, it may be that the acute effects
associated mainly with NSAID use, which leads to the
development of AF. The fact that recent past users who,
according to their prescription, also stopped using
NSAIDs in the preceding 30 days had a higher risk of AF
can be explained if symptoms lead to discontinuation of
the NSAID. Also, it is possible that they might still be
using it at the index date or still have active drug levels.
Several mechanisms might explain the association of
NSAIDs with risk of AF. It is possible that NSAIDs play a
causal role in the development of AF, as they inhibit
cyclo-oxygenase.29 Cyclo-oxygenase enzymes are expressed
in kidney tissue.29 Inhibition of these enzymes may lead to
Table 3 The association of NSAID use with risk of atrial fibrillation, additionally adjusted for left ventricular end-diastolic
dimension at baseline (N=4919)
Model 1* Model 2†
n HR 95% CI HR 95% CI
Never use 24 1 (Ref.) 1 (Ref.)
Current use (days)
≤14 0 NA (NA) NA (NA)
15–30 5 3.61 (1.37 to 9.50) 3.21 (1.22 to 8.48)
>30 3 1.97 (0.59 to 6.56) 1.71 (0.51 to 5.70)
Past use (days)
≤30 6 1.61 (0.66 to 3.94) 1.47 (0.60 to 3.62)
31–180 13 1.14 (0.58 to 2.24) 1.03 (0.52 to 2.03)
>180 128 1.42 (0.92 to 2.20) 1.32 (0.85 to 2.06)
*Adjusted for age at index date, sex and left ventricular end-diastolic dimension.
†Additionally adjusted for baseline values of: systolic blood pressure, diastolic blood pressure, body mass index, total and HDL cholesterol,
smoking status and left ventricular end-diastolic dimension. Time dependent covariates include: blood pressure lowering drugs, history of
myocardial infarction, presence of heart failure, prevalent diabetes.
HDL, high-density lipoprotein; n, number of atrial fibrillation cases; NA, not applicable; NSAID, non-steroidal anti-inflammatory drug.
Table 2 The association of NSAID use with risk of atrial fibrillation
Model 1* Model 2†
n HR 95% CI HR 95% CI
Never use 261 1 (Ref.) 1 (Ref.)
Current use (days)
≤14 17 1.08 (0.66 to 1.76) 0.96 (0.59 to 1.58)
15–30 17 1.99 (1.22 to 3.26) 1.76 (1.07 to 2.88)
>30 8 1.00 (0.50 to 2.03) 0.84 (0.41 to 1.70)
Past use (days)
≤30 47 2.01 (1.47 to 2.75) 1.84 (1.34 to 2.51)
31–180 76 1.10 (0.85 to 1.42) 1.00 (0.77 to 1.29)
>180 431 1.11 (0.94 to 1.30) 1.04 (0.88 to 1.22)
No use 815 1 (Ref.) 1 (Ref.)
Dosage current use
Low-medium dosage (PDD ≤1) 24 1.09 (0.73 to 1.64) 0.97 (0.65 to 1.46)
High dosage (PDD >1.0) 18 1.33 (0.83 to 2.11) 1.27 (0.80 to 2.03)
*Adjusted for age at index date and sex.
†Additionally adjusted for baseline values of: systolic blood pressure, diastolic blood pressure, body mass index, total and HDL cholesterol,
smoking status. Time dependent covariates include: blood pressure lowering drugs, history of myocardial infarction, presence of heart failure,
prevalent diabetes.
HDL, high-density lipoprotein; n, number of atrial fibrillation cases; NSAID, non-steroidal anti-inflammatory drug; PDD, prescribed daily
dosage.
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an increase in blood pressure due to fluid retention,
increased peripheral resistance and attenuation of diuretic
and antihypertensive drug effects.9 29 It was shown that
current NSAID use is associated with increased end-
diastolic and end-systolic dimension obtained with echo-
cardiography in the first 14 days of treatment with
NSAIDs, and with end-diastolic dimension alone after
longer use.15 Possibly these changes in left ventricular
dimensions could explain part of the association between
NSAIDs and atrial fibrillation. In a sensitivity analysis in
patients for whom echocardiography was available, we
adjusted for baseline left ventricular end-diastolic dimen-
sion in a subsample of our population. In this analysis, left
ventricular end-diastolic dimension was indeed associated
with a higher risk of AF. After adjustment for left ventricu-
lar end-diastolic dimension, NSAID use remained asso-
ciated with the risk of AF. However, as end-diastolic
diameter at the moment of AF was not available, it is pos-
sible that NSAID use through fluid retention and increas-
ing end-diastolic of end-systolic dimension increases the
risk of AF. Moreover, COX inhibition may lead to fluctu-
ation of serum potassium by decreased excretion in the
distal nephron.29 Possibly these adverse renal effects may
trigger AF.6 9 However, it is also possible that NSAID use is
an indicator of the presence of the underlying inflamma-
tory disease. These underlying inflammatory conditions
might be associated with the risk of AF.30
Our study has several strengths. We included follow-up
data from the RS, which is based on the general popula-
tion and contains detailed information on drug expos-
ure. Compared with previous database studies, we were
able to use more detailed information for a range of
potential confounders and to adjust for established risk
factors of AF such as blood pressure and BMI, and in a
subsample for echocardiographic measures. Also, we
were able to use a more accurate clinical assessment of
AF. We used three different methods for case gathering
and assessment, as we included every clinically recog-
nised case from two different sources of medical
records. In addition, we included repeated screening
ECG assessments of the study population at the research
centre. Compared with the previously published studies,
however, our sample size was smaller. This might explain
why some of our estimations did not reach statistical sig-
nificance. Also, we only had data available prescribed on
NSAIDs and did not have information on the indication
for the prescription nor on the use of NSAIDs that were
bought without a prescription. Finally, we were not able
to categorise according to COX selectivity because of
the low number of users of COX-1 and COX-2
inhibitors.
In conclusion, we found that use of NSAIDs is asso-
ciated with an increased risk of AF. Current use and
recent past use were especially associated with a higher
risk of AF, adjusted for age, sex and cardiovascular risk
factors. The underlying mechanism behind this associ-
ation deserves further attention.
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